ZDHHC14

Summary

ZDHHC14 (zDHHC palmitoyltransferase 14, HGNC:20341) is a protein-coding gene on chromosome 6q25.3, encoding Palmitoyltransferase ZDHHC14 (Q8IZN3). Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates.

Enables palmitoyltransferase activity. Involved in peptidyl-L-cysteine S-palmitoylation. Located in endoplasmic reticulum.

Source: NCBI Gene 79683 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 67 total
• MANE Select transcript: NM_024630

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20341
Approved symbol	ZDHHC14
Name	zDHHC palmitoyltransferase 14
Location	6q25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20984, NEW1CP
Ensembl gene	ENSG00000175048
Ensembl biotype	protein_coding
OMIM	619295
Entrez	79683

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 13 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000340347, ENST00000341375, ENST00000359775, ENST00000414563, ENST00000422910, ENST00000517432, ENST00000518214, ENST00000523468, ENST00000523706, ENST00000931192, ENST00000931193, ENST00000931194, ENST00000931195, ENST00000931196, ENST00000931197, ENST00000931198, ENST00000970775, ENST00000970776, ENST00000970777

RefSeq mRNA: 2 — MANE Select: NM_024630 NM_024630, NM_153746

CCDS: CCDS47510, CCDS5252

Canonical transcript exons

ENST00000359775 — 9 exons

Exon	Start	End
ENSE00001218308	157542585	157542745
ENSE00002118840	157672724	157678157
ENSE00003476787	157653525	157653627
ENSE00003518850	157632834	157632882
ENSE00003561284	157592988	157593146
ENSE00003623638	157645737	157645839
ENSE00003685100	157628349	157628486
ENSE00003685478	157647259	157647368
ENSE00003850525	157381190	157382266

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 94.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.2714 / max 10746.2823, expressed in 1726 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
70757	6.3648	1322
70766	4.5467	467
70759	3.9495	1378
70767	3.5302	444
70768	0.8733	167
70758	0.5041	276
204270	0.2528	62
70760	0.2499	111

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	94.52	gold quality
buccal mucosa cell	CL:0002336	93.89	gold quality
spinal cord	UBERON:0002240	93.83	gold quality
endothelial cell	CL:0000115	91.77	gold quality
middle temporal gyrus	UBERON:0002771	91.59	gold quality
tendon of biceps brachii	UBERON:0008188	90.99	gold quality
decidua	UBERON:0002450	89.83	gold quality
body of uterus	UBERON:0009853	89.82	gold quality
inferior vagus X ganglion	UBERON:0005363	89.78	gold quality
inferior olivary complex	UBERON:0002127	89.67	gold quality
prefrontal cortex	UBERON:0000451	89.43	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.41	gold quality
amygdala	UBERON:0001876	89.33	gold quality
right frontal lobe	UBERON:0002810	89.07	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.74	gold quality
cerebellar hemisphere	UBERON:0002245	88.54	gold quality
cerebellar cortex	UBERON:0002129	88.47	gold quality
cervix squamous epithelium	UBERON:0006922	88.35	silver quality
anterior cingulate cortex	UBERON:0009835	88.22	gold quality
cingulate cortex	UBERON:0003027	88.20	gold quality
Ammon’s horn	UBERON:0001954	88.15	gold quality
periodontal ligament	UBERON:0008266	88.11	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.07	gold quality
cerebellum	UBERON:0002037	88.00	gold quality
Brodmann (1909) area 23	UBERON:0013554	87.91	gold quality
frontal cortex	UBERON:0001870	87.76	gold quality
temporal lobe	UBERON:0001871	87.68	gold quality
medial globus pallidus	UBERON:0002477	87.64	gold quality
neocortex	UBERON:0001950	87.51	gold quality
primary visual cortex	UBERON:0002436	87.44	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	45.72
E-ANND-3	no	3.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting ZDHHC14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-891A-3P	98.05	67.99	970
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-647	97.73	67.79	927
HSA-MIR-4690-3P	97.02	64.72	981

Literature-anchored findings (GeneRIF, showing 3)

• Identify ZDHHC14 as a novel tumour suppressor gene that is commonly down-regulated in testicular germ cell tumours and prostate cancer. (PMID:24407904)
• Results indicate that ZDHHC14 is involved in tumor progression in patients with scirrhous type gastric cancer. (PMID:24807047)
• The palmitoyl acyltransferase ZDHHC14 controls Kv1-family potassium channel clustering at the axon initial segment. (PMID:33185190)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc14	ENSDARG00000037069
mus_musculus	Zdhhc14	ENSMUSG00000034265
rattus_norvegicus	Zdhhc14	ENSRNOG00000029049
drosophila_melanogaster	app	FBGN0260941
caenorhabditis_elegans	dhhc-12	WBGENE00010323
caenorhabditis_elegans	dhhc-2	WBGENE00012948
caenorhabditis_elegans		WBGENE00016620

Paralogs (17): ZDHHC6 (ENSG00000023041), ZDHHC15 (ENSG00000102383), ZDHHC2 (ENSG00000104219), ZDHHC4 (ENSG00000136247), ZDHHC7 (ENSG00000153786), ZDHHC1 (ENSG00000159714), ZDHHC12 (ENSG00000160446), ZDHHC3 (ENSG00000163812), ZDHHC19 (ENSG00000163958), ZDHHC21 (ENSG00000175893), ZDHHC22 (ENSG00000177108), ZDHHC20 (ENSG00000180776), ZDHHC23 (ENSG00000184307), ZDHHC9 (ENSG00000188706), ZDHHC11 (ENSG00000188818), ZDHHC18 (ENSG00000204160), ZDHHC11B (ENSG00000206077)

Protein

Protein identifiers

Palmitoyltransferase ZDHHC14 — Q8IZN3 (reviewed: Q8IZN3)

Alternative names: DHHC domain-containing cysteine-rich protein 14, NEW1 domain-containing protein, Zinc finger DHHC domain-containing protein 14

All UniProt accessions (3): Q8IZN3, H0Y2Y4, H0YAX0

UniProt curated annotations — full annotation on UniProt →

Function. Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates. May have a palmitoyltransferase activity toward the beta-2 adrenergic receptor/ADRB2 and thereby regulate G protein-coupled receptor signaling. May play a role in cell differentiation and apoptosis.

Subcellular location. Endoplasmic reticulum membrane. Golgi apparatus. Golgi stack membrane.

Tissue specificity. Widely expressed.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Similarity. Belongs to the DHHC palmitoyltransferase family. ERF2/ZDHHC9 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IZN3-1	1	yes
Q8IZN3-2	2

RefSeq proteins (2): NP_078906, NP_714968 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain
IPR039859	PFA4/ZDH16/20/ERF2-like	Family

Pfam: PF01529

Catalyzed reactions (Rhea), 1 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)

UniProt features (15 total): topological domain 5, transmembrane region 4, chain 1, domain 1, active site 1, modified residue 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZN3-F1	73.43	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 195 (s-palmitoyl cysteine intermediate)

Post-translational modifications (1): 455

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 203 (showing top): RRAGTTGT_UNKNOWN, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, SP3_Q3, GOBP_PROTEIN_TARGETING, GGGTGGRR_PAX4_03, GOBP_PEPTIDYL_CYSTEINE_MODIFICATION, AACWWCAANK_UNKNOWN, chr6q25, IRF7_01, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, MARTINEZ_RB1_TARGETS_DN, RAMALHO_STEMNESS_DN, GOBP_LIPOPROTEIN_BIOSYNTHETIC_PROCESS, TGTGTGA_MIR377, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (2): protein targeting to membrane (GO:0006612), peptidyl-L-cysteine S-palmitoylation (GO:0018230)

GO Molecular Function (4): palmitoyltransferase activity (GO:0016409), protein-cysteine S-palmitoyltransferase activity (GO:0019706), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (5): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), Golgi cisterna membrane (GO:0032580), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
organelle membrane	2
protein targeting	1
establishment of protein localization to membrane	1
peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine	1
protein palmitoylation	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
palmitoyltransferase activity	1
protein-cysteine S-acyltransferase activity	1
catalytic activity	1
transferase activity	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
Golgi cisterna	1
cellular anatomical structure	1

Protein interactions and networks

STRING

562 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC14	DLG2	Q15700	532
ZDHHC14	ZDHHC3	Q9NYG2	506
ZDHHC14	ZDHHC22	Q8N966	500
ZDHHC14	TMEM131	Q92545	483
ZDHHC14	ZNF813	Q6ZN06	477
ZDHHC14	AMIGO3	Q86WK7	472
ZDHHC14	MCF2L2	Q86YR7	456
ZDHHC14	TMEM242	Q9NWH2	444
ZDHHC14	GOLGA7	Q7Z5G4	434
ZDHHC14	LRCH3	Q96II8	418
ZDHHC14	KAZN	Q674X7	416
ZDHHC14	ZDHHC7	Q9NXF8	413
ZDHHC14	ZDHHC5	Q9C0B5	396
ZDHHC14	ZDHHC13	Q8IUH4	393
ZDHHC14	RBL1	P28749	390

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SLC46A3	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): ZDHHC14 (Affinity Capture-RNA), ZDHHC14 (Affinity Capture-RNA), ZDHHC14 (Proximity Label-MS), ZDHHC14 (Proximity Label-MS), ZDHHC14 (Affinity Capture-MS), ZDHHC14 (Co-purification), ZDHHC14 (Proximity Label-MS), ZDHHC14 (Cross-Linking-MS (XL-MS)), ZDHHC14 (Affinity Capture-MS), ZDHHC14 (Proximity Label-MS), ZDHHC14 (Affinity Capture-RNA)

ESM2 similar proteins: A0A571BF63, A0JMQ9, A0JN69, A1L1R5, E7EZI4, O41933, P0C7U3, P33279, P40145, P97490, Q0IH10, Q0VD59, Q11122, Q1L8G6, Q1LVZ2, Q28EX7, Q28GL3, Q28IK8, Q32L65, Q3UF64, Q4R8E0, Q5I0I2, Q5M7Z0, Q5PQ35, Q5RAG4, Q5T0T0, Q5XH39, Q5XIE5, Q68FA7, Q6NRX0, Q6NTV1, Q6NZ21, Q6NZQ8, Q6ZPS6, Q6ZUJ8, Q803Q4, Q86UD3, Q8BGN6, Q8BPQ7, Q8BRX9

Diamond homologs: A0A0R4IDP3, A2CEX1, A2VEY9, A5WVX9, B3DN87, C8VCL4, E1BLT8, E7F021, E7F587, E7FBS9, E7FH11, E9PTT0, E9QCD3, F1Q7H8, F1QAM1, F1QHM7, F1QX91, F1QXD3, F1R013, F1RE57, J9VJ99, O60069, O74384, O80685, P42836, P59267, P59268, Q04629, Q0VC89, Q10L01, Q2TGJ1, Q2TGJ4, Q2TGK3, Q2THW7, Q2THW8, Q2THW9, Q2THX0, Q2THX1, Q4R690, Q4WZL8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4094 predictions. Top by Δscore:

Variant	Effect	Δscore
6:157382265:GA:G	donor_gain	1.0000
6:157382267:G:GG	donor_gain	1.0000
6:157542562:C:CA	acceptor_gain	1.0000
6:157542563:G:A	acceptor_gain	1.0000
6:157542567:T:TA	acceptor_gain	1.0000
6:157542572:A:AG	acceptor_gain	1.0000
6:157542572:AACCT:A	acceptor_gain	1.0000
6:157542576:T:TA	acceptor_gain	1.0000
6:157542579:C:A	acceptor_gain	1.0000
6:157542734:A:T	donor_gain	1.0000
6:157542738:GCAAA:G	donor_gain	1.0000
6:157542742:A:AG	donor_gain	1.0000
6:157592985:CA:C	acceptor_loss	1.0000
6:157592986:A:AG	acceptor_gain	1.0000
6:157592987:G:GG	acceptor_gain	1.0000
6:157592987:GA:G	acceptor_gain	1.0000
6:157592987:GAT:G	acceptor_gain	1.0000
6:157593143:GTAG:G	donor_gain	1.0000
6:157653520:CGCA:C	acceptor_loss	1.0000
6:157653521:GCAG:G	acceptor_loss	1.0000
6:157653522:CAG:C	acceptor_loss	1.0000
6:157653523:A:AG	acceptor_gain	1.0000
6:157653523:AG:A	acceptor_loss	1.0000
6:157653524:G:GA	acceptor_gain	1.0000
6:157653524:GCCT:G	acceptor_gain	1.0000
6:157653623:ACATG:A	donor_gain	1.0000
6:157382263:TCGAG:T	donor_loss	0.9900
6:157382266:AGTAA:A	donor_loss	0.9900
6:157382268:TAAGT:T	donor_loss	0.9900
6:157542573:A:G	acceptor_gain	0.9900

AlphaMissense

3212 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:157382178:G:T	G53W	1.000
6:157382179:G:T	G53V	1.000
6:157542691:G:A	G118R	1.000
6:157542691:G:C	G118R	1.000
6:157542692:G:A	G118E	1.000
6:157542692:G:T	G118V	1.000
6:157593033:G:C	R151T	1.000
6:157593034:A:C	R151S	1.000
6:157593034:A:T	R151S	1.000
6:157593068:A:G	K163E	1.000
6:157593072:T:C	L164P	1.000
6:157593074:A:G	K165E	1.000
6:157593075:A:C	K165T	1.000
6:157593075:A:T	K165I	1.000
6:157593076:A:C	K165N	1.000
6:157593076:A:T	K165N	1.000
6:157593077:T:G	Y166D	1.000
6:157593078:A:C	Y166S	1.000
6:157593078:A:G	Y166C	1.000
6:157593080:T:A	C167S	1.000
6:157593080:T:C	C167R	1.000
6:157593080:T:G	C167G	1.000
6:157593081:G:A	C167Y	1.000
6:157593081:G:C	C167S	1.000
6:157593081:G:T	C167F	1.000
6:157593082:T:G	C167W	1.000
6:157593083:T:C	F168L	1.000
6:157593085:C:A	F168L	1.000
6:157593085:C:G	F168L	1.000
6:157593089:T:A	C170S	1.000

dbSNP variants (sampled 300 via entrez): RS1000011710 (6:157631371 G>A), RS1000014528 (6:157675103 C>T), RS1000027361 (6:157391947 G>A,C,T), RS1000029699 (6:157554744 C>G,T), RS1000066463 (6:157604255 C>G), RS1000078733 (6:157383528 G>A), RS1000110765 (6:157525115 ATGAGCCTTGCCATG>A), RS1000118327 (6:157604544 T>G), RS1000137340 (6:157474658 G>A), RS1000144120 (6:157615813 T>G), RS1000146755 (6:157435497 T>C), RS1000154655 (6:157669466 G>T), RS1000163031 (6:157541896 A>G), RS1000166853 (6:157408371 C>T), RS1000172687 (6:157533216 G>A,T)

Disease associations

OMIM: gene MIM:619295 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001308_14	Response to anti-depressant treatment in major depressive disorder	3.000000e-06
GCST004570_10	Iron status biomarkers (iron levels)	9.000000e-10
GCST004616_183	Platelet distribution width	2.000000e-16
GCST007637_25	Diffusing capacity of carbon monoxide	9.000000e-07
GCST008157_13	Body fat mass	7.000000e-06
GCST012490_173	Femur bone mineral density x serum urate levels interaction	3.000000e-08
GCST90002395_493	Mean platelet volume	2.000000e-13
GCST90002395_494	Mean platelet volume	9.000000e-16
GCST90002401_541	Platelet distribution width	4.000000e-47

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006321	antidepressant-induced dizziness
EFO:0007984	platelet component distribution width
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	6
Valproic Acid	affects expression, increases expression, increases methylation	4
Aflatoxin B1	decreases expression, increases methylation, affects methylation	3
bisphenol A	affects cotreatment, affects methylation, decreases expression, increases methylation	2
Arsenic	affects cotreatment, increases abundance, increases expression, affects methylation	2
Cisplatin	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	decreases methylation	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
zinc chromate	decreases expression, increases abundance	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
versicolorin A	decreases expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
ICG 001	increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, affects methylation	1
Acetaminophen	decreases expression	1
Benzene	decreases expression	1
Dexamethasone	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Lead	affects expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TY70	HAP1 ZDHHC14 (-) 1	Cancer cell line	Male
CVCL_TY71	HAP1 ZDHHC14 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.